mFOLFOX7+Camrelizumab+Apatinib

Phase 2Small molecule

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

mFOLFOX7+Camrelizumab+Apatinib is one of 3 small molecule programs targeting Camrelizumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CamrelizumabRecruiting

CamrelizumabPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Camrelizumab

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 3

11 2

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 3

7 3

mFOLFOX7+Camrelizumab+Apatinib

SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Camrelizumab1 trial

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05412589·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mFOLFOX7+Camrelizumab+Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mFOLFOX7+Camrelizumab+Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mFOLFOX7+Camrelizumab+Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

mFOLFOX7+Camrelizumab+Apatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Camrelizumab1 trial

References

Drug Info

Quick Facts

Related News